We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	Youtube
Purpose	External media

Research

Research Group Cancer Drug Development

Dr. Aubry Miller / Dr. Nikolas Gunkel

The translation of new cancer research findings into novel therapeutics is of fundamental importance in the path toward A Life Without Cancer. The Cancer Drug Development Group takes the first step along this path: the discovery and development of small molecules with specific inhibitory profiles and phenotypic effects. These small molecule inhibitors can be used as research tools to help elucidate the role(s) that target proteins play in cancer, and can be starting points for more advanced drug development projects. Research projects in our group tackle topics such as target identification and validation, assay development for high throughput screening, chemical synthesis for inhibitor optimization and the development of chemical biology probes, and the establishment of cellular assays to profile our inhibitors. By collaborating with colleagues who are experts in basic, as well as, clinical research, we have established a unique academic drug discovery environment embedded in the scientific excellence of the DKFZ and NCT.

FUTURE OUTLOOK

We aim to work on innovative targets with clear clinical significance, and on new targets/pathways whose roles in cancer have yet to be fully unraveled.

We are part of the Helmholtz Drug Research Initiative and the DKTK.

Contact

Dr. Aubry Miller / Dr. Nikolas Gunkel

Cancer Drug Development (A390)

Deutsches Krebsforschungszentrum

Im Neuenheimer Feld 580

69120 Heidelberg

Dr. Aubry Miller
Tel: +49 6221 42 3307
Contact Form

Dr. Nikolas Gunkel
Tel: +49 6221 42 3419
Contact Form

Selected Publications

Geraldy, M. et al. “Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated” J. Med. Chem. 2019, ASAP; DOI: 10.1021/acs.jmedchem.8b01936
De Vita, E. et al. “Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity” J. Med. Chem. 2018, 61, 8859–8874.
Lohbeck, J., Miller, A. “Practical Synthesis of a Phthalimide-Based Cereblon Ligand to Enable PROTAC Development” Bioorg. Med. Chem. Lett. 2016, 26, 5260–5262.
Morgen, M. et al. “Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity” ACS Chem Biol. 2016, 11, 1001–1011.